Humanized Cobra Venom Factor Complement Depletion Biologics

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Biologics therapies often induce unwanted immunogenicity, leading to ineffective treatment and adverse events such as anaphylaxis, due to the immune response they trigger, which poses significant clinical challenges.

Innovation Solution

Humanized cobra venom factor (hCVF) is administered to deplete complement levels, reducing or preventing immunogenicity and allowing repeated use, thereby enhancing the efficacy and safety of biologic therapies by suppressing the production of antibodies against therapeutic proteins.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If biologics therapy is administered to treat disease, then therapeutic efficacy is improved, but unwanted immunogenicity increases

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoidunwanted immunogenicity
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces complement depletion as an intermediary mechanism between the biologic therapy and the immune system. By depleting complement components before and during biologic administration, the harmful immune response is blocked without affecting the therapeutic effect, thus resolving the contradiction between efficacy and immunogenicity

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary complement depletion before biologic therapy administration to prevent immunogenicity from developing. This pre-action creates a protective state that allows the biologic to work effectively without triggering unwanted immune responses, addressing the contradiction proactively

Inventive Principle:
Principle #10Preliminary action

2Duration of action of moving object

If biologics therapy is administered repeatedly, then treatment duration is extended, but immunogenicity accumulates

Engineering Contradiction:
Improvetreatment durationVSAvoidaccumulated immunogenicity
Core Design Contradiction:
Duration of action of moving objectVSObject-generated harmful factors

Solution Approach 1:

The patent implements preliminary complement depletion before each repeated biologic administration to prevent immunogenicity accumulation. This ensures that each treatment cycle starts with a clean immune state, allowing extended treatment duration without accumulating harmful immune responses

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent establishes a periodic pattern of complement depletion followed by biologic administration. This cyclic approach allows repeated treatments to be given systematically, maintaining therapeutic efficacy while preventing immunogenicity accumulation through regular immune system reset

Inventive Principle:
Principle #19Periodic action

3Object-generated harmful factors

If complement is depleted to reduce immunogenicity, then unwanted immune responses are reduced, but complement-related functions are impaired

Engineering Contradiction:
Improveunwanted immune responsesVSAvoidcomplement-related functions
Core Design Contradiction:
Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent applies partial complement depletion rather than complete elimination. By depleting complement to a controlled extent, the patent reduces unwanted immune responses while preserving sufficient complement activity for essential biological functions, thus resolving the contradiction between reducing harm and maintaining reliability

Inventive Principle:
Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

hCVF effectively depletes complement levels, reducing immunogenicity and adverse reactions, allowing for repeated administration of biologic therapies without inducing significant immune responses, thereby improving treatment outcomes for conditions like hemophilia A and other complement-related disorders.

Implementation Method 1

The administration of the agent and hCVF can be a second or a subsequent administration to the subject, with the immune response being reduced or prevented by the second or subsequent administration.

Methodology Applied
Scientific EffectComplement depletion:

Data Source

PatentEP3154639B1Uses of humanized cobra venom factor for reducing or preventing immunogenicity
Publication Date: 2020.09.02 UNIV OF HAWAII
  • EP3154639B1 patent drawingFigure 1
  • EP3154639B1 patent drawingFigure 2
  • EP3154639B1 patent drawingFigure 3

AI summary

The embodiments herein are concerned with methods and hCVF compositions, including pharmaceutical formulations, useful in complement depletion, the reduction or prevention of unwanted immunogenicity or other immune-related reactions, especially as a consequence of administering a biologic therapy. Such methods and compositions have been found to be effective in complement depletion during more than one administration in the same subject, thereby being useful for prolonged/repeated use.